Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Anthony S. Fischl"'
Autor:
Rupal S. Bhatt, Laura E. Benjamin, David C. Alsop, Damien Gerald, Sudhakar Chintharlapalli, Mark T. Uhlik, Jason Manro, Philip Hipskind, Takako Wilson, Julie Stewart, Glenn Evans, Diane Bodenmiller, Rowena Almonte-Baldonado, Beverly L. Falcon, Xiaoen Wang, Anthony S. Fischl
Inhibition of VEGFR signaling is an effective treatment for renal cell carcinoma, but resistance continues to be a major problem. Recently, the sphingosine phosphate (S1P) signaling pathway has been implicated in tumor growth, angiogenesis, and resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07698e2d3dbef68e4960d1e590a94e57
https://doi.org/10.1158/1535-7163.c.6537817.v1
https://doi.org/10.1158/1535-7163.c.6537817.v1
Autor:
Rupal S. Bhatt, Laura E. Benjamin, David C. Alsop, Damien Gerald, Sudhakar Chintharlapalli, Mark T. Uhlik, Jason Manro, Philip Hipskind, Takako Wilson, Julie Stewart, Glenn Evans, Diane Bodenmiller, Rowena Almonte-Baldonado, Beverly L. Falcon, Xiaoen Wang, Anthony S. Fischl
Figure S2: Co-targeting S1P1 and VEGFR2 pathways induced reduction in permeability of retinal vessels. Ter 119 staining (panels A) visualize red blood cells and show that the combination of DC101 and the S1P1 antagonist in the retina led to reduction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f131b36c3fff3a476b481e429735e4
https://doi.org/10.1158/1535-7163.22504639
https://doi.org/10.1158/1535-7163.22504639
Autor:
Gregory P. Donoho, Hai H. Bui, Diane M. Bodenmiller, Anthony S. Fischl, Ming Shang Kuo, Phillip E. Sanders
Publikováno v:
Analytical Biochemistry. 547:66-76
Phosphatidylinositol (3,4,5) trisphosphate (PIP3) is a biologically active membrane phospholipid that is essential for the growth and survival of all eukaryotic cells. We describe a new method that directly measures PIP3 and describe the HPLC separat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::483a33e7f88cdabd5dbaeb3655ef5f8a
https://doi.org/10.1016/j.ab.2018.02.014
https://doi.org/10.1016/j.ab.2018.02.014
Autor:
Diane M. Bodenmiller, Jeeyun Lee, Alberto Santamaria-Pang, Shou-Ching S. Jaminet, Yunxia Sui, Aejaz Nasir, Julie Stewart, Fiona Ginty, Anthony S. Fischl, Keyur Desai, Larry E. Douglass, Yousef Al-Kofahi, Thompson N. Doman, Harold F. Dvorak, Hilal Celikkaya, Damien Gerald, Bronislaw Pytowski, Cynthia Jeffries, Seema Iyer, Sudhakar Chintharlapalli, Amit Aggarwal, Christina Lowes, Mark T. Uhlik, Jiangang Liu, Beverly L. Falcon, Marguerita O’Mahony, Christopher J. Sevinsky, Julia H. Carter, Laura E. Benjamin, Janice A. Nagy, Qi Xue
Publikováno v:
Cancer Research. 76:2573-2586
Treatment of metastatic gastric cancer typically involves chemotherapy and monoclonal antibodies targeting HER2 (ERBB2) and VEGFR2 (KDR). However, reliable methods to identify patients who would benefit most from a combination of treatment modalities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac918e9f03cbcf6da2908307ebce6c4d
https://doi.org/10.1158/0008-5472.can-16-0022
https://doi.org/10.1158/0008-5472.can-16-0022
Publikováno v:
Cancer Research. 80:1675-1675
Background: NSCLC accounts for nearly 85% of all lung cancers. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for EGFR mutated NSCLCs, but these drugs often stop working after EGFR acquires additional mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01ab3b779547ddb3ba3d2f1aab9a62d9
https://doi.org/10.1158/1538-7445.am2020-1675
https://doi.org/10.1158/1538-7445.am2020-1675
Autor:
Takako Wilson, Julie Stewart, Sudhakar Chintharlapalli, Mark T. Uhlik, Xiaoen Wang, Rowena Almonte-Baldonado, David C. Alsop, Damien Gerald, Beverly L. Falcon, Rupal S. Bhatt, Laura E. Benjamin, Jason Manro, Philip Arthur Hipskind, Anthony S. Fischl, Glenn F. Evans, Diane M. Bodenmiller
Publikováno v:
Molecular cancer therapeutics. 18(4)
Inhibition of VEGFR signaling is an effective treatment for renal cell carcinoma, but resistance continues to be a major problem. Recently, the sphingosine phosphate (S1P) signaling pathway has been implicated in tumor growth, angiogenesis, and resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21306f2da006c674c9d76ed8a963b2c5
https://pubmed.ncbi.nlm.nih.gov/30787172
https://pubmed.ncbi.nlm.nih.gov/30787172
Autor:
Hai H, Bui, Phillip E, Sanders, Diane, Bodenmiller, Ming Shang, Kuo, Gregory P, Donoho, Anthony S, Fischl
Publikováno v:
Analytical biochemistry. 547
Phosphatidylinositol (3,4,5) trisphosphate (PIP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8725d1d62d5940048c57048698a1d8c0
https://pubmed.ncbi.nlm.nih.gov/29470948
https://pubmed.ncbi.nlm.nih.gov/29470948
Publikováno v:
Journal of Magnetic Resonance Imaging. 36:459-467
Purpose: To evaluate the reproducibility of the measurement of the total choline-to-water ratio, and the effect of repositioning the subject between scans, using 1H-magnetic resonance spectroscopy in a mouse U87MG xenograft model. Materials and Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99327a0db4bcde4f7da5d5368a484a49
https://doi.org/10.1002/jmri.23664
https://doi.org/10.1002/jmri.23664
Publikováno v:
Analytical Biochemistry. 314:97-107
Phospholipid molecules such as ceramide and phosphoinositides play crucial roles in signal transduction pathways. Lipid-modifying enzymes including sphingomyelinase and phosphoinositide kinases regulate the generation and degradation of these lipid-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50caa54652ec3621b3e469dc2cc50f6f
https://doi.org/10.1016/s0003-2697(02)00616-4
https://doi.org/10.1016/s0003-2697(02)00616-4
Autor:
Diane M. Bodenmiller, Julie Stewart, Sau-Chi Betty Yan, Anthony S. Fischl, Victoria L. Peek, Glenn F. Evans, Jennifer R. Stephens, Seema Iyer, Sudhakar Chintharlapalli, Xi Lin, Beverly L. Falcon
Publikováno v:
Cancer Research. 77:1823-1823
Merestinib (LY2801653) is an orally bioavailable small molecule inhibitor of several oncokinases, including MET, AXL, DDR1/2, MERTK, ROS1, Tie2 (aka TEK), and MKNK1/2. Merestinib has been extensively characterized in a wide range of preclinical tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88b083a0c77354d50ad7c2459ce74536
https://doi.org/10.1158/1538-7445.am2017-1823
https://doi.org/10.1158/1538-7445.am2017-1823